radionuclide therapy is widely used as an effective modality in the management of bone pain. the main indication for this treatment is symptomatic bone metastases, confirmed by bone scintigraphy. we present a case of small cell lung cancer (sclc) stage t4n2m1b, with a good metabolic response to systemic therapy and radiotherapy of the primary tumor and locoregional disease, which became metabol...

Symptomatic hypocalcaemia is an uncommon finding in patients with malignant tumours. We describe a patient with advanced metastatic breast cancer who developed severe hypocalcaemia caused by the combination of osteoblastic metastases and a permanent postoperative hypoparathyroidism. The patient failed to be treated with the conventional replacement therapy and was submitted effectively to radio...

Introduction: Use of SPECT/CT data is the most accurate method for patient-specific internal dosimetry when isotopes emit single gamma rays. The manual or semi-automatic segmentation of organs is a major obstacle that slows down and limits the patient-specific dosimetry. Using digital phantoms that mimic patient’s anatomy can bypass the segmentation step and facilitate the dosi...

introduction: various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153sm-edtmp. in this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. methods: 153sm-tthmp was prepared starting from 153sm-smcl3, prepared by neutro...

Introduction: Various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153Sm-EDTMP. In this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. Methods: 153Sm-TTHMP was prepared starting from 153<...

PURPOSE This open-label, phase I dose-escalation study assessed the safety, tolerability, and initial efficacy of Samariam 153 (153Sm)-lexidronam/bortezomib combination therapy for patients with relapsed/refractory multiple myeloma. EXPERIMENTAL DESIGN Patients were enrolled in six cohorts and given bortezomib (1.0 or 1.3 mg/m2) on days 1, 4, 8, and 11 and 153Sm-lexidronam (0.25, 0.5, or 1.0 ...

Radionuclide therapy is widely used as an effective modality in the management of bone pain. The main indication for this treatment is symptomatic bone metastases, confirmed by bone scintigraphy. We present a case of small cell lung cancer (SCLC) stage T4N2M1b, with a good metabolic response to systemic therapy and radiotherapy of the primary tumor and locoregional disease, which became metabol...

Introduction: Bone pain palliation therapy is a mandate in handling end-stage cancer patients. The development of new ligands with higher stability, better pharmacokinetics and lower unwanted tissue uptakes (liver and GI) is still ongoing. Methods: In this work Lu-177 labeled (3-amino-1-hydroxypropane-1,1-di-yl)-bis-(phosphonate) (177Lu-pamidronate; 177Lu-PAM ), ...

BACKGROUND Metastatic bone lesion is a common syndrome of many cancer diseases in an advanced state. The major symptom is severe pain, spinal cord compression, and pathological fracture, associated with an obvious morbidity. Common treatments including systemic application of bisphosphonate drugs aim on pain reduction and on improving the quality of life of the patient. Particularly, patients w...